鹽酸恩諾沙星
|
|
|
- CAS號:
- 93106-59-3
- 英文名:
- ENROFLOXAIN HYDROCHLORIDE
- 英文別名:
- ENROFLOXAIN HYDROCHLORIDE;3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI)
- 中文名:
- 鹽酸恩諾沙星
- 中文別名:
- 恩諾沙星單鹽酸鹽;化合物 Enrofloxacin monohydrochloride;Enrofloxacin monohydrochloride #天然產(chǎn)物 HY-B0502A;Enrofloxacin monohydrochloride #天然產(chǎn)物 HY-B0502A;化合物：Enrofloxacin monohydrochloride CAS:93106-59-3;化合物:Enrofloxacin monohydrochloride CAS:93106-59-3
- CBNumber:
- CB91504238
- 分子式:
- C19H23ClFN3O3
- 分子量:
- 395.8556232
- MOL File:
- 93106-59-3.mol
|
|
|
鹽酸恩諾沙星化學(xué)性質(zhì)
-
儲存條件:
-
Store at -20°C
-
|
-
溶解度:
-
H2O: 2?mg/mL, clear (Warmed)
-
|
-
形態(tài):
-
Solid
-
|
-
顏色:
-
White to off-white
-
|
-
水溶解性:
-
Water : 7.14 mg/mL (Need ultrasonic)
-
|
-
InChI:
-
InChI=1S/C19H22FN3O3.ClH/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12;/h9-12H,2-8H2,1H3,(H,25,26);1H
-
|
-
InChIKey:
-
PZJWYUDBXNNVLZ-UHFFFAOYSA-N
-
|
-
SMILES:
-
N1(C2CC2)C2=C(C=C(F)C(N3CCN(CC)CC3)=C2)C(=O)C(C(O)=O)=C1.[H]Cl
-
|
鹽酸恩諾沙星性質(zhì)、用途與生產(chǎn)工藝
Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) 是一種有效的抗生素，作用于 Mycoplasma bovis，MIC90 為 0.312 μg/ mL。
MIC90: 0.312 μg/mL (
Mycoplasma bovis
)
Mycoplasma bovis
is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL.
Mice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment.
鹽酸恩諾沙星
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS編號 | 包裝 | 價格 |
|---|
| 2026/06/05 | HY-B0502AR | 鹽酸恩諾沙星
Enrofloxacin monohydrochloride (Standard) | 93106-59-3 | 10 mg | 340元 |
| 2026/06/05 | HY-B0502AR | 鹽酸恩諾沙星
Enrofloxacin monohydrochloride (Standard) | 93106-59-3 | 25 mg | 660元 |
93106-59-3, 鹽酸恩諾沙星 相關(guān)搜索:
- Pharmacutical raw materials
- 抑制劑
- 醫(yī)藥原料
- 獸藥原料
- 化合物 Enrofloxacin monohydrochloride
- Enrofloxacin monohydrochloride #天然產(chǎn)物 HY-B0502A
- 化合物：Enrofloxacin monohydrochloride CAS:93106-59-3
- Enrofloxacin monohydrochloride #天然產(chǎn)物 HY-B0502A
- 化合物:Enrofloxacin monohydrochloride CAS:93106-59-3
- 恩諾沙星單鹽酸鹽
- 93106-59-3
- 3-Quinolinecarboxylic acid, 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-, Monohydrochloride (9CI)
- ENROFLOXAIN HYDROCHLORIDE